|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
JANSSEN PHARMACEUTICA N.V.
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Conduct disorders in children |
|
Psychosis |
|
Tourette's syndrome |
| |
|
|
SIDE EFFECTS:
|
|
Akathisia |
|
dystonic extrapyramidal effects |
|
parkinsonian extrapyramidal effects |
|
Allergic reaction |
|
anticholinergic effects |
|
CNS effect |
|
decreased thirst, or unusual tiredness or weakness |
|
orthostatic hypotension |
|
persistent tardive dyskinesia |
|
Agranulocytosis |
|
heat stroke |
|
obstructive jaundice |
|
neuroleptic malignant syndrome (NMS) |
|
tardive dystonia |
|
Blurred vision |
|
changes in menstrual period |
|
constipation |
|
dryness of mouth |
|
swelling or soreness in breasts in females |
|
unusual secretion of milk |
|
weight gain |
|
Decreased sexual ability |
|
drowsiness |
|
increased sensitivity of skin to sun |
|
nausea or vomiting |
|
Withdrawal emergent dyskinesia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Alcoholism, active |
|
>> Cardiovascular disease, severe, especially angina |
|
>> Epilepsy |
|
Glaucoma or predisposition to |
|
Hepatic function impairment |
|
Hyperthyroidism or thyrotoxicosis |
|
>> Parkinson's disease |
|
Pulmonary insufficiency, such as asthma, emphysema, or acute pulmonary infections |
|
Renal function impairment |
|
>> Sensitivity to haloperidol |
|
>> Urinary retention |
|
|
ADULT DOSE:
|
|
Antipsychotic; antidyskinetic-Oral, 500 mcg (0.5 mg) to 5 mg two or three times a day initially, the dosage being gradually adjusted as needed and tolerated . |
|
MAXIMUM ADULT DOSE:
|
|
100 mg a day .
|
|
PEDIATRIC DOSE:
|
|
Psychotic disorders-Children younger than 3 years of age: Safety and efficacy have not been established .
Children 3 to l2 years of age or 15 to 40 kg of body weight: Oral, initially 50 mcg (0.05 mg) per kg of body weight a day (in two or three divided doses), the daily dose being increased as needed and tolerated by 500-mcg (0.5 mg) increments at five- to seven-day intervals up to a total of 150 mcg (0.150 mg) per kg of body weight a day .
Nonpsychotic behavior disorders and Tourette's syndrome-Children younger than 3 years of age: Safety and efficacy have not been established .
Children 3 to l2 years of age or 15 to 40 kg of body weight: Oral, initially 50 mcg (0.05 mg) per kg of body weight a day (in two or three divided doses), the daily dose being increased as needed and tolerated by 500-mcg (0.5 mg) increments at five- to seven-day intervals up to a total of 75 mcg (0.075 mg) per kg of body weight a day .
Alternatively, some clinicians recommend that, in the treatment of Tourette's syndrome, the initial daily dose be administered at bedtime to avoid daytime sedation .
[Infantile autism] -Children younger than 3 years of age: Safety and efficacy have not been established .
Children 3 to l2 years of age or 15 to 40 kg of body weight: Oral, 25 mcg (0.025 mg) per kg of body weight a day, up to 50 mcg (0.05 mg) per kg of body weight a day.
Note: There is little evidence that pediatric dosages exceeding 6 mg a day produce additional improvement in behavior or in tics . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Oral, 500 mcg (0.5 mg) to 2 mg two or three times a day, the dosage being increased gradually as needed and tolerated .
Note: The dose for debilitated patients is the same as the geriatric dose .
|
|
|
|
|
|